NorthWest Biotherapeutics Inc (NWBO)

[iclight]

Gee, nobody has ever seen good results in an tiny early stage trial before that failed to translate to a larger population with an actual control arm in a well run RCT trial.

Results from a small, single-institution, phase 1 study of ICT-107 in 16 newly diagnosed patients with glioblastoma showed that median progression-free survival (PFS) was 16.9 months, and the 5-year rate of PFS was 37.5%; median overall survival (OS) was 38.4 months, and the 5-year rate of OS was 50%.3

Why aren't all GBM patients using ICT-107? Oh that's right, because in the large P2 it didn't work. Just like DCVax with Poly IF they ever run a confirmatory P3.